# Soteria Biotherapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/soteria-biotherapeutics

- Industry: Biotechnology
- Headquarters: San Francisco, US
- Website: www.soteriabiotherapeutics.com
- Total disclosed funding: $25M
- Latest round: Series A (May 4, 2021)
- Investors on record: 5

## About

Soteria Biotherapeutics, Inc. is a US-based company focused on developing biopharmaceutical solutions to tackle significant health issues, particularly in autoimmune diseases and cancer treatment.Founded in 2018 and headquartered in San Francisco, US, Soteria Biotherapeutics, Inc. specializes in biopharmaceutical advancements. The company is led by Founder Alexander Martinko, who has a history of founding similar firms. Soteria's most recent funding was a Series A round on May 4, 2021, raising USD 24.90 mn from investors including 5AM Ventures, Alexandria Venture Investments, M Ventures, Novartis Venture Fund, and Roche Venture Fund. The company has completed one deal to date, with a current valuation of USD 38.47 mn.Soteria Biotherapeutics specializes in developing innovative biopharmaceutical solutions aimed at addressing critical health challenges, particularly in autoimmune diseases and cancer therapies. Their core offerings include advanced monoclonal antibodies and targeted therapies designed to modulate immune responses and inhibit tumor growth, enhancing treatment efficacy while minimizing adverse effects. The company focuses on North American and European markets, collaborating with healthcare institutions and research organizations to facilitate the adoption of its therapies, primarily serving hospitals, clinics, and specialty pharmacies.Soteria Biotherapeutics generates revenue through a structured model that combines direct sales and partnerships with healthcare providers and pharmaceutical distributors. They sell products through wholesale distributors or directly to hospitals and clinics, offering various pricing plans to cater to client needs. The revenue model includes ongoing collaborations and potential licensing agreements that support their market presence and financial sustainability.In May 2021, Soteria Biotherapeutics, Inc. raised USD 24.90 mn in Series A funding to advance its technology and develop a pipeline of T-LITE candidates targeting well-validated cancer indications. The company plans to utilize this funding to launch new products and expand into new geographic markets, enhancing their therapeutic offerings and market reach.

## Funding rounds

- Series A, May 4, 2021, $25M — Novartis Venture Fund, Alexandria Venture Investments, 5AM Ventures, Roche Venture Fund, M Ventures

## Investors

- Novartis Venture Fund (https://capitalatlas.ai/funds/novartis-venture-fund) — Series A
- Alexandria Venture Investments (https://capitalatlas.ai/funds/alexandria-venture-investments) — Series A
- 5AM Ventures (https://capitalatlas.ai/funds/5am-ventures) — Series A
- Roche Venture Fund (https://capitalatlas.ai/funds/roche-venture-fund) — Series A
- M Ventures (https://capitalatlas.ai/funds/m-ventures) — Series A